Developing disease-modifying neuropathic pain therapies that reverse pathophysiology, relieve chronic pain, and potentially cure it

Targeting Pain at Its Source

Our therapeutic strategy deploys specific human monoclonal antibodies to inactivate certain matrix metalloproteinases – MMP-9 and MMP-14. Our therapy can potentially improve outcomes for patients suffering from severe neuropathic pain, whose only current treatment option is opioids, which can be addictive and cause severe side effects. Patients suffering from moderate chronic pain who are currently dependent on anti-seizure and anti-depressant medications, can also potentially benefit from Releviate therapy. Our studies will further test the safety and efficacy of our therapeutic.

The Cost of Pain

Chronic pain is the largest indication in the world and the #1 reason for doctors visits in the U.S. Approximately 100 million adults in the U.S. are affected by chronic pain each year. The annual total cost of pain – including direct costs, decreased wages, and lost productivity – eclipses that of any other condition.

Diabetes $170 Billion
Cancer $250 Billion
Cardiovascular Disease $270 Billion
Chronic Pain Over $600 Billion

A New Discovery

Researchers are aggressively studying the potential role MMPs play in the progression of different oncological and autoimmune diseases. However, only recently Releviate basic, translational and clinical scientists determined the role of some MMPs in pain.

Read More

Addressing Unmet Needs in Chronic Pain

There is significant pre-clinical evidence that Releviate’s therapy is disease-modifying, reversing underlying pathophysiology leading to the neuropathic pain onset and maintenance. Based on this new insight into mechanisms of neuropathic pain, a Releviate-associated team developed patented, human monoclonal antibodies that inactivate MMP-9 and MMP-14.

Releviate holds an exclusive license for the technology. READ MORE

Releviate is currently initiating the regulatory process for clinical studies to assess the safety and efficacy for two indications: small fiber neuropathy (SFN) – our lead indication, diabetes-induced neuropathic pain (DNP).


Find Out More